Maryland-based MacroGenics, (NASDAQ: MGNX), a biopharma focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, has provided an update on its lead antibody-drug conjugate (ADC) vobramitamab duocarmazine (vobra duo).
Vobra duo targets B7-H3, an antigen with broad expression across multiple solid tumors and a member of the B7 family of molecules involved in immune regulation.
MacroGenics is developing the ADC for people with metastatic castration-resistant prostate cancer (mCRPC), as a second-line option.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze